首页> British journal of haematology> Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.

导出 OA

翻译打印收藏纠错

第一作者： Andrzej J,Jakubowiak

第一单位： University of Chicago Medical Center, Chicago, IL, USA.

作者： Andrzej J,Jakubowiak ^[1] ; Jagoda K,Jasielec ^[1] ; Cara A,Rosenbaum ^[2] ; Craig E,Cole ^[3] ; Ajai,Chari ^[4] ; Joseph,Mikhael ^[5] ; Jennifer,Nam ^[1] ; Amanda,McIver ^[1] ; Erica,Severson ^[1] ; Leonor A,Stephens ^[1] ; Kathryn,Tinari ^[1] ; Shaun,Rosebeck ^[1] ; Todd M,Zimmerman ^[1] ; Tyler,Hycner ^[1] ; Agata,Turowski ^[1] ; Theodore,Karrison ^[1] ; Jeffrey A,Zonder ^[6]

作者单位： University of Chicago Medical Center, Chicago, IL, USA. ^[1] Weill Cornell Medical College, New York, NY, USA. ^[2] Department of Medicine, Division of Hematology/Oncology, University of Michigan School of Medicine, Ann Arbor, MI, USA. ^[3] Tisch Cancer Institute/Multiple Myeloma Program, Mount Sinai School of Medicine, New York, NY, USA. ^[4] Mayo Clinic, Phoenix, AZ, and International Myeloma Foundation, Los Angeles, CA, USA. ^[5] Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA. ^[6]

关键词 carfilzomib dexamethasone relapsed/refractory multiple myeloma selinexor